Trade Assembly Biosciences, Inc. - ASMB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2022 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 10.6589 |
| Open | 10.5589 |
| 1-Year Change | -19.38% |
| Day's Range | 10.5589 - 10.8889 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 11, 2025 | 10.6589 | -0.2000 | -1.84% | 10.8589 | 11.0589 | 10.5189 |
| Mar 10, 2025 | 10.8589 | -0.1000 | -0.91% | 10.9589 | 11.7189 | 10.7489 |
| Mar 7, 2025 | 11.0789 | -0.3800 | -3.32% | 11.4589 | 11.6389 | 10.7589 |
| Mar 6, 2025 | 11.4289 | -0.4600 | -3.87% | 11.8889 | 11.8889 | 11.2289 |
| Mar 5, 2025 | 11.7089 | 0.1300 | 1.12% | 11.5789 | 12.1089 | 11.0289 |
| Mar 4, 2025 | 11.7089 | -0.4500 | -3.70% | 12.1589 | 12.1589 | 11.3189 |
| Mar 3, 2025 | 12.1889 | -0.6600 | -5.14% | 12.8489 | 12.8889 | 12.1889 |
| Feb 28, 2025 | 12.6689 | -0.2000 | -1.55% | 12.8689 | 12.8689 | 12.4589 |
| Feb 27, 2025 | 12.7089 | -0.1500 | -1.17% | 12.8589 | 12.9589 | 12.6789 |
| Feb 26, 2025 | 13.0689 | 0.6100 | 4.90% | 12.4589 | 13.4789 | 12.3589 |
| Feb 25, 2025 | 12.1589 | -0.2100 | -1.70% | 12.3689 | 12.6089 | 12.1589 |
| Feb 24, 2025 | 12.3189 | -0.4400 | -3.45% | 12.7589 | 12.8989 | 12.2589 |
| Feb 21, 2025 | 12.3089 | -0.2000 | -1.60% | 12.5089 | 12.9589 | 12.1989 |
| Feb 20, 2025 | 12.4689 | -0.1300 | -1.03% | 12.5989 | 13.5889 | 12.2889 |
| Feb 19, 2025 | 12.6789 | 0.3700 | 3.01% | 12.3089 | 13.2889 | 12.3089 |
| Feb 18, 2025 | 12.4389 | -0.0300 | -0.24% | 12.4689 | 12.9589 | 12.2589 |
| Feb 14, 2025 | 12.7989 | 0.5900 | 4.83% | 12.2089 | 13.1789 | 12.2089 |
| Feb 13, 2025 | 12.1189 | -0.4400 | -3.50% | 12.5589 | 12.5589 | 12.0589 |
| Feb 12, 2025 | 12.5289 | -0.4300 | -3.32% | 12.9589 | 12.9589 | 12.3389 |
| Feb 11, 2025 | 13.0389 | -0.0200 | -0.15% | 13.0589 | 13.2889 | 12.9589 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Assembly Biosciences, Inc. Company profile
About Assembly Biosciences Inc
Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Assembly Biosciences Inc revenues decreased 92% to $6.3M. Net loss increased from $62.2M to $129.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest and other income, net decrease of 88% to $302K (income), Restructuring Charges & Provisions increase of 40% to $277K (expense).
Equity composition
Common Stock $0.001 Par, 4/11, 25M auth., 7,189,706 issd.insider control 7.88%. 07-14, 1-for-5 reverse stock split.
| Industry: | Proprietary & Advanced Pharmaceuticals |
Two Tower Place
7Th Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com